This content is machine translated Highlights from the AAD Annual Meeting Atopic Dermatitis: Interesting News on Drug Candidates in Phase III At the 2026 Annual Meeting of the American Academy of Dermatology (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The...…
